» Articles » PMID: 24530938

Does the HPV Vaccination Programme Have Implications for Cervical Screening Programmes in the UK?

Overview
Journal Vaccine
Date 2014 Feb 18
PMID 24530938
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

In the UK, a national HPV immunisation programme was implemented in 2008 for girls aged 12-13 years. In addition a catch-up programme was implemented for older girls up to 18 years of age from 2009 to 2011, with an uptake rate of 49.4%. Information about future uptake of cervical screening according to vaccination statistics is important in order to understand the impact of the vaccination programme and implications for a national cervical screening programme. We analysed data on a cohort of women who had been offered the HPV vaccine in the catch-up programme and were invited for cervical screening between 2010 and 2012 in Wales (n=30,882), in a record-linked database study, to describe the cervical screening uptake and clinical outcome according to HPV vaccination status. In our cohort, 48.5% (n=14,966) women had had HPV vaccination and 45.9% (n=14,164) women attended for cervical screening. Women who were unvaccinated were less likely to attend cervical screening (adjusted OR 0.58; 95% CI (0.55, 0.61)). Of those who attended for screening, 13.9% of vaccinated women had abnormal cytology reported compared to 16.7% of women who were unvaccinated. Women who lived in areas with high levels of social deprivation were less likely to be vaccinated (Quintile 5 OR 0.48 95% CI (0.45, 0.52)) or attend cervical screening (Quintile 5 OR 0.70; 95% CI (0.65, 0.75)) compared to those who lived in the least deprived areas. These data highlight the need for new strategies to address inequalities in cervical screening uptake and can inform further mathematical modelling work to clarify the impact of the HPV vaccination programme on future cervical cancer incidence.

Citing Articles

A transversal cross-sectional study of factors related to HPV vaccination status and cancer screening participation among French women aged 25-40.

Serman F, Lisembard G, Sahraoui M, Berkhout C, Rochoy M, Haro A BMC Cancer. 2024; 24(1):807.

PMID: 38971725 PMC: 11227699. DOI: 10.1186/s12885-024-12591-1.


Effect of the HPV vaccination programme on incidence of cervical cancer and grade 3 cervical intraepithelial neoplasia by socioeconomic deprivation in England: population based observational study.

Falcaro M, Soldan K, Ndlela B, Sasieni P BMJ. 2024; 385:e077341.

PMID: 38749552 PMC: 11094700. DOI: 10.1136/bmj-2023-077341.


Social factors and age play a significant role in cervical cancer and advanced-stage disease among Danish women.

Bonlokke S, Blaakaer J, Steiniche T, Iachina M BMC Cancer. 2024; 24(1):259.

PMID: 38395802 PMC: 10893677. DOI: 10.1186/s12885-024-11994-4.


Association of human papillomavirus vaccination with cervical cancer screening: A systematic review and meta-analysis.

Ssentongo P, McCall-Hosenfeld J, Calo W, Moss J, Lengerich E, Chinchilli V Medicine (Baltimore). 2022; 101(28):e29329.

PMID: 35839062 PMC: 11132352. DOI: 10.1097/MD.0000000000029329.


Cervical cancer screening guidelines and screening practices in 11 countries: A systematic literature review.

Wang W, Arca E, Sinha A, Hartl K, Houwing N, Kothari S Prev Med Rep. 2022; 28:101813.

PMID: 35637896 PMC: 9142642. DOI: 10.1016/j.pmedr.2022.101813.


References
1.
Castellsague X, Munoz N, Pitisuttithum P, Ferris D, Monsonego J, Ault K . End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. Br J Cancer. 2011; 105(1):28-37. PMC: 3137403. DOI: 10.1038/bjc.2011.185. View

2.
Paavonen J, Naud P, Salmeron J, Wheeler C, Chow S, Apter D . Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009; 374(9686):301-14. DOI: 10.1016/S0140-6736(09)61248-4. View

3.
Schwarz T, Spaczynski M, Schneider A, Wysocki J, Galaj A, Schulze K . Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15-55 years. Hum Vaccin. 2011; 7(9):958-65. PMC: 3225769. DOI: 10.4161/hv.7.9.15999. View

4.
Lehtinen M, Paavonen J, Wheeler C, Jaisamrarn U, Garland S, Castellsague X . Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2011; 13(1):89-99. DOI: 10.1016/S1470-2045(11)70286-8. View

5.
Bowyer H, Marlow L, Hibbitts S, Pollock K, Waller J . Knowledge and awareness of HPV and the HPV vaccine among young women in the first routinely vaccinated cohort in England. Vaccine. 2013; 31(7):1051-6. DOI: 10.1016/j.vaccine.2012.12.038. View